BGM-0504

The rapid development of China's biopharmaceutical industry, especially the rise of the GLP-1 weight loss drug market, has aroused widespread concern. However, behind the boom in this sector, some companies are facing serious challenges. In the case of Sino Biopharm, a company that once stood out for its innovative product BGM0504 and the charisma of its leaders, is now suffering from the cold face of the market, and the sharp decline in its share price reveals deep problems within the industry. First of all, the competitiveness of Chinese GLP-1 drugs in the global market still needs to be improved. Although Chinese companies have made some progress in molecular design and clinical trials, there is still a clear gap in the competition with international pharmaceutical giants such as Novo Nordisk and Eli Lilly. According to the data of international pharmaceutical market research institutions, in 2020, China's GLP-1 drug share in the global market is only 6%, reflecting the lack of Chinese enterprises in technology research and development and global market layout, which limits its overseas authorization and cooperation opportunities to a certain extent. Secondly, excessive market expectations have brought huge pressure to enterprises. At one point Sino Biopharm's market capitalisation was more than twice that of the API company, a "bubble-like" valuation that reflected excessive investor optimism about its future profitability. However, pharmaceutical innovation requires long-term research and development investment and time accumulation, with the continuous rise of research and development costs, enterprises can achieve profitable growth as scheduled, the market is cautious about this. In addition, some enterprises are too pursuit of short-term market effects, ignoring the fundamental quality and safety of products. In the fierce market competition, some enterprises may choose to sacrifice product quality in exchange for short-term market share, such short-sighted behavior not only harms the long-term development of enterprises, but also may trigger a crisis of public trust in the entire industry. The development of pharmaceutical innovation industry needs rationality and stability. Enterprises should focus on improving the core competitiveness of products, and gradually narrow the gap with international leading enterprises through continuous research and development investment and technological innovation. At the same time, investors also need to have a deeper understanding of the industry, a rational view of the relationship between the market heat and the actual value of the enterprise, in order to achieve the long-term stable development of the industry and the capital market. Only in this way can China's biopharmaceutical industry continue to grow in the face of challenges and achieve sustainable prosperity.